Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications

莫达非尼 嗜睡症 猝倒 哌醋甲酯 睡眠麻痹 医学 白天过度嗜睡 心理学 药理学 睡眠障碍 精神科 失眠症 注意缺陷多动障碍
作者
Michael J. Thorpy,Richard Bogan
出处
期刊:Sleep Medicine [Elsevier BV]
卷期号:68: 97-109 被引量:74
标识
DOI:10.1016/j.sleep.2019.09.001
摘要

Narcolepsy is a chronic, debilitating neurological disorder of sleep-wake state instability. This instability underlies all narcolepsy symptoms, including excessive daytime sleepiness (EDS), symptoms of rapid eye movement (REM) sleep dysregulation (ie, cataplexy, hypnagogic/hypnopompic hallucinations, sleep paralysis), and disrupted nighttime sleep. Several neurotransmitter systems promote wakefulness, and various neural pathways are involved in regulating REM sleep-related muscle atonia, providing multiple targets for pharmacologic intervention to reduce EDS and cataplexy. Medications approved by the US Food and Drug Administration (FDA) for the treatment of EDS in narcolepsy include traditional stimulants (eg, amphetamines, methylphenidate), wake-promoting agents (eg, modafinil, armodafinil), and solriamfetol, which mainly act on dopaminergic and noradrenergic pathways. Sodium oxybate (thought to act via GABAB receptors) is FDA-approved for the treatment of EDS and cataplexy. Pitolisant, a histamine 3 (H3)-receptor antagonist/inverse agonist, is approved by the European Medicines Agency (EMA) for the treatment of narcolepsy with or without cataplexy in adults and by the FDA for the treatment of EDS in adults with narcolepsy. Pitolisant increases the synthesis and release of histamine in the brain and modulates the release of other neurotransmitters (eg, norepinephrine, dopamine). Antidepressants that inhibit reuptake of serotonin and/or norepinephrine are widely used off label to manage cataplexy. In many patients with narcolepsy, combination treatment with medications that act via different neural pathways is necessary for optimal symptom management. Mechanism of action, pharmacokinetics, and abuse potential are important considerations in treatment selection and subsequent medication adjustments to maximize efficacy and mitigate adverse effects in the treatment of patients with narcolepsy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yishu完成签到,获得积分10
1秒前
酷酷柚子发布了新的文献求助10
1秒前
舒舒的应助被闫霄溯采纳,获得10
1秒前
ICH完成签到,获得积分10
1秒前
hhh发布了新的文献求助10
2秒前
巅峰囚冰完成签到,获得积分10
2秒前
xu1227发布了新的文献求助10
2秒前
简单豆芽完成签到,获得积分10
2秒前
2秒前
2秒前
灵巧绿海发布了新的文献求助10
3秒前
3秒前
AKTAO发布了新的文献求助10
3秒前
3秒前
5秒前
刘威完成签到,获得积分10
5秒前
柚子瓤发布了新的文献求助10
5秒前
聪慧若风完成签到,获得积分10
5秒前
vicluwang完成签到,获得积分10
6秒前
Hiker发布了新的文献求助10
7秒前
7秒前
饱满的醉冬完成签到 ,获得积分10
7秒前
a1313发布了新的文献求助10
8秒前
8秒前
apple发布了新的文献求助10
8秒前
ljj发布了新的文献求助10
9秒前
Rocky完成签到,获得积分10
9秒前
NexusExplorer的应助被惠惠采纳,获得10
9秒前
zenzero完成签到,获得积分10
9秒前
10秒前
10秒前
深情安青的应助被酷酷柚子采纳,获得10
11秒前
whyzz发布了新的文献求助10
11秒前
极限001的应助被dxxxxx采纳,获得30
11秒前
12秒前
Gibson完成签到,获得积分10
12秒前
12秒前
a1313完成签到,获得积分10
12秒前
13秒前
领导范儿的应助被Shaka采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183204
求助须知:如何正确求助?哪些是违规求助? 9572482
关于积分的说明 21825940
捐赠科研通 7780074
什么是DOI,文献DOI怎么找? 3433945
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480166